img

Global Vaccine for Non-infectious Meningitis Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Vaccine for Non-infectious Meningitis Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Meningococcal conjugate vaccine is used to prevent infection caused by meningococcal bacteria.
The global Vaccine for Non-infectious Meningitis market size was US$ 1 million in 2022 and is forecast to a readjusted size of US$ 2 million by 2034 with a CAGR of 12.0% during the forecast period 2024-2034.
The United States market for Vaccine for Non-infectious Meningitis is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Vaccine for Non-infectious Meningitis is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Vaccine for Non-infectious Meningitis is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Vaccine for Non-infectious Meningitis include Serum Institute, Sanofi SA, Pfizer, Nuron Biotech and JN-International Medical, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Vaccine for Non-infectious Meningitis, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Vaccine for Non-infectious Meningitis by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Vaccine for Non-infectious Meningitis market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Vaccine for Non-infectious Meningitis market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Serum Institute
Sanofi SA
Pfizer
Nuron Biotech
JN-International Medical
By Type
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
Men B Vaccines
By Application
Meningitis
Septicemia
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Vaccine for Non-infectious Meningitis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Vaccine for Non-infectious Meningitis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine for Non-infectious Meningitis sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Vaccine for Non-infectious Meningitis Definition
1.2 Market by Type
1.2.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Polysaccharide Vaccines
1.2.3 Conjugate Vaccines
1.2.4 Combination Vaccines
1.2.5 Men B Vaccines
1.3 Market Segment by Application
1.3.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Meningitis
1.3.3 Septicemia
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Vaccine for Non-infectious Meningitis Sales
2.1 Global Vaccine for Non-infectious Meningitis Revenue Estimates and Forecasts 2018-2034
2.2 Global Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Vaccine for Non-infectious Meningitis Revenue by Region
2.3.1 Global Vaccine for Non-infectious Meningitis Revenue by Region (2018-2024)
2.3.2 Global Vaccine for Non-infectious Meningitis Revenue by Region (2024-2034)
2.4 Global Vaccine for Non-infectious Meningitis Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Vaccine for Non-infectious Meningitis Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Vaccine for Non-infectious Meningitis Sales Quantity by Region
2.6.1 Global Vaccine for Non-infectious Meningitis Sales Quantity by Region (2018-2024)
2.6.2 Global Vaccine for Non-infectious Meningitis Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Vaccine for Non-infectious Meningitis Sales Quantity by Manufacturers
3.1.1 Global Vaccine for Non-infectious Meningitis Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Vaccine for Non-infectious Meningitis Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Vaccine for Non-infectious Meningitis Sales in 2022
3.2 Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers
3.2.1 Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers (2018-2024)
3.2.2 Global Vaccine for Non-infectious Meningitis Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Vaccine for Non-infectious Meningitis Revenue in 2022
3.3 Global Vaccine for Non-infectious Meningitis Sales Price by Manufacturers
3.4 Global Key Players of Vaccine for Non-infectious Meningitis, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaccine for Non-infectious Meningitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Product Offered and Application
3.8 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Vaccine for Non-infectious Meningitis Sales Quantity by Type
4.1.1 Global Vaccine for Non-infectious Meningitis Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Vaccine for Non-infectious Meningitis Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
4.2 Global Vaccine for Non-infectious Meningitis Revenue by Type
4.2.1 Global Vaccine for Non-infectious Meningitis Historical Revenue by Type (2018-2024)
4.2.2 Global Vaccine for Non-infectious Meningitis Forecasted Revenue by Type (2024-2034)
4.2.3 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
4.3 Global Vaccine for Non-infectious Meningitis Price by Type
4.3.1 Global Vaccine for Non-infectious Meningitis Price by Type (2018-2024)
4.3.2 Global Vaccine for Non-infectious Meningitis Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Vaccine for Non-infectious Meningitis Sales Quantity by Application
5.1.1 Global Vaccine for Non-infectious Meningitis Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Vaccine for Non-infectious Meningitis Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
5.2 Global Vaccine for Non-infectious Meningitis Revenue by Application
5.2.1 Global Vaccine for Non-infectious Meningitis Historical Revenue by Application (2018-2024)
5.2.2 Global Vaccine for Non-infectious Meningitis Forecasted Revenue by Application (2024-2034)
5.2.3 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
5.3 Global Vaccine for Non-infectious Meningitis Price by Application
5.3.1 Global Vaccine for Non-infectious Meningitis Price by Application (2018-2024)
5.3.2 Global Vaccine for Non-infectious Meningitis Price Forecast by Application (2024-2034)
6 North America
6.1 North America Vaccine for Non-infectious Meningitis Sales by Company
6.1.1 North America Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024)
6.1.2 North America Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024)
6.2 North America Vaccine for Non-infectious Meningitis Market Size by Type
6.2.1 North America Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2034)
6.2.2 North America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2034)
6.3 North America Vaccine for Non-infectious Meningitis Market Size by Application
6.3.1 North America Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2034)
6.3.2 North America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2034)
6.4 North America Vaccine for Non-infectious Meningitis Market Size by Country
6.4.1 North America Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2034)
6.4.3 North America Vaccine for Non-infectious Meningitis Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Vaccine for Non-infectious Meningitis Sales by Company
7.1.1 Europe Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024)
7.1.2 Europe Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024)
7.2 Europe Vaccine for Non-infectious Meningitis Market Size by Type
7.2.1 Europe Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2034)
7.2.2 Europe Vaccine for Non-infectious Meningitis Revenue by Type (2018-2034)
7.3 Europe Vaccine for Non-infectious Meningitis Market Size by Application
7.3.1 Europe Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2034)
7.3.2 Europe Vaccine for Non-infectious Meningitis Revenue by Application (2018-2034)
7.4 Europe Vaccine for Non-infectious Meningitis Market Size by Country
7.4.1 Europe Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Vaccine for Non-infectious Meningitis Revenue by Country (2018-2034)
7.4.3 Europe Vaccine for Non-infectious Meningitis Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Vaccine for Non-infectious Meningitis Sales by Company
8.1.1 China Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024)
8.1.2 China Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024)
8.2 China Vaccine for Non-infectious Meningitis Market Size by Type
8.2.1 China Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2034)
8.2.2 China Vaccine for Non-infectious Meningitis Revenue by Type (2018-2034)
8.3 China Vaccine for Non-infectious Meningitis Market Size by Application
8.3.1 China Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2034)
8.3.2 China Vaccine for Non-infectious Meningitis Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Vaccine for Non-infectious Meningitis Sales by Company
9.1.1 APAC Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024)
9.1.2 APAC Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024)
9.2 APAC Vaccine for Non-infectious Meningitis Market Size by Type
9.2.1 APAC Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2034)
9.2.2 APAC Vaccine for Non-infectious Meningitis Revenue by Type (2018-2034)
9.3 APAC Vaccine for Non-infectious Meningitis Market Size by Application
9.3.1 APAC Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2034)
9.3.2 APAC Vaccine for Non-infectious Meningitis Revenue by Application (2018-2034)
9.4 APAC Vaccine for Non-infectious Meningitis Market Size by Region
9.4.1 APAC Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Vaccine for Non-infectious Meningitis Revenue by Region (2018-2034)
9.4.3 APAC Vaccine for Non-infectious Meningitis Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Company
10.1.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Type
10.2.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Application
10.3.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Country
10.4.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Serum Institute
11.1.1 Serum Institute Company Information
11.1.2 Serum Institute Overview
11.1.3 Serum Institute Vaccine for Non-infectious Meningitis Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Serum Institute Vaccine for Non-infectious Meningitis Products and Services
11.1.5 Serum Institute Vaccine for Non-infectious Meningitis SWOT Analysis
11.1.6 Serum Institute Recent Developments
11.2 Sanofi SA
11.2.1 Sanofi SA Company Information
11.2.2 Sanofi SA Overview
11.2.3 Sanofi SA Vaccine for Non-infectious Meningitis Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Sanofi SA Vaccine for Non-infectious Meningitis Products and Services
11.2.5 Sanofi SA Vaccine for Non-infectious Meningitis SWOT Analysis
11.2.6 Sanofi SA Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Vaccine for Non-infectious Meningitis Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Pfizer Vaccine for Non-infectious Meningitis Products and Services
11.3.5 Pfizer Vaccine for Non-infectious Meningitis SWOT Analysis
11.3.6 Pfizer Recent Developments
11.4 Nuron Biotech
11.4.1 Nuron Biotech Company Information
11.4.2 Nuron Biotech Overview
11.4.3 Nuron Biotech Vaccine for Non-infectious Meningitis Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Nuron Biotech Vaccine for Non-infectious Meningitis Products and Services
11.4.5 Nuron Biotech Vaccine for Non-infectious Meningitis SWOT Analysis
11.4.6 Nuron Biotech Recent Developments
11.5 JN-International Medical
11.5.1 JN-International Medical Company Information
11.5.2 JN-International Medical Overview
11.5.3 JN-International Medical Vaccine for Non-infectious Meningitis Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 JN-International Medical Vaccine for Non-infectious Meningitis Products and Services
11.5.5 JN-International Medical Vaccine for Non-infectious Meningitis SWOT Analysis
11.5.6 JN-International Medical Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Vaccine for Non-infectious Meningitis Value Chain Analysis
12.2 Vaccine for Non-infectious Meningitis Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccine for Non-infectious Meningitis Production Mode & Process
12.4 Vaccine for Non-infectious Meningitis Sales and Marketing
12.4.1 Vaccine for Non-infectious Meningitis Sales Channels
12.4.2 Vaccine for Non-infectious Meningitis Distributors
12.5 Vaccine for Non-infectious Meningitis Customers
13 Market Dynamics
13.1 Vaccine for Non-infectious Meningitis Industry Trends
13.2 Vaccine for Non-infectious Meningitis Market Drivers
13.3 Vaccine for Non-infectious Meningitis Market Challenges
13.4 Vaccine for Non-infectious Meningitis Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Polysaccharide Vaccines
Table 3. Major Manufacturers of Conjugate Vaccines
Table 4. Major Manufacturers of Combination Vaccines
Table 5. Major Manufacturers of Men B Vaccines
Table 6. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Vaccine for Non-infectious Meningitis Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2018-2024)
Table 10. Global Vaccine for Non-infectious Meningitis Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2024-2034)
Table 12. Global Vaccine for Non-infectious Meningitis Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Vaccine for Non-infectious Meningitis Sales by Region (2018-2024) & (K Units)
Table 14. Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2018-2024)
Table 15. Global Vaccine for Non-infectious Meningitis Sales by Region (2024-2034) & (K Units)
Table 16. Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2024-2034)
Table 17. Global Vaccine for Non-infectious Meningitis Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Vaccine for Non-infectious Meningitis Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Vaccine for Non-infectious Meningitis Revenue Share by Manufacturers (2018-2024)
Table 21. Global Vaccine for Non-infectious Meningitis Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Key Players of Vaccine for Non-infectious Meningitis, Industry Ranking, 2021 VS 2022
Table 23. Global Vaccine for Non-infectious Meningitis Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Vaccine for Non-infectious Meningitis by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vaccine for Non-infectious Meningitis as of 2022)
Table 25. Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Product Offered and Application
Table 27. Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Vaccine for Non-infectious Meningitis Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Vaccine for Non-infectious Meningitis Sales Quantity Share by Type (2018-2024)
Table 32. Global Vaccine for Non-infectious Meningitis Sales Quantity Share by Type (2024-2034)
Table 33. Global Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Vaccine for Non-infectious Meningitis Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Vaccine for Non-infectious Meningitis Revenue Share by Type (2018-2024)
Table 36. Global Vaccine for Non-infectious Meningitis Revenue Share by Type (2024-2034)
Table 37. Vaccine for Non-infectious Meningitis Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Vaccine for Non-infectious Meningitis Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Vaccine for Non-infectious Meningitis Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Vaccine for Non-infectious Meningitis Sales Quantity Share by Application (2018-2024)
Table 42. Global Vaccine for Non-infectious Meningitis Sales Quantity Share by Application (2024-2034)
Table 43. Global Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Vaccine for Non-infectious Meningitis Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Vaccine for Non-infectious Meningitis Revenue Share by Application (2018-2024)
Table 46. Global Vaccine for Non-infectious Meningitis Revenue Share by Application (2024-2034)
Table 47. Vaccine for Non-infectious Meningitis Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Vaccine for Non-infectious Meningitis Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Vaccine for Non-infectious Meningitis Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Vaccine for Non-infectious Meningitis Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Vaccine for Non-infectious Meningitis Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Vaccine for Non-infectious Meningitis Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Vaccine for Non-infectious Meningitis Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Vaccine for Non-infectious Meningitis Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Vaccine for Non-infectious Meningitis Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Vaccine for Non-infectious Meningitis Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Vaccine for Non-infectious Meningitis Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Vaccine for Non-infectious Meningitis Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Vaccine for Non-infectious Meningitis Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Vaccine for Non-infectious Meningitis Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Vaccine for Non-infectious Meningitis Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Vaccine for Non-infectious Meningitis Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Vaccine for Non-infectious Meningitis Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Vaccine for Non-infectious Meningitis Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Vaccine for Non-infectious Meningitis Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Vaccine for Non-infectious Meningitis Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Vaccine for Non-infectious Meningitis Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Vaccine for Non-infectious Meningitis Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Vaccine for Non-infectious Meningitis Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity by Country (2024-2034) & (K Units)
Table 119. Serum Institute Company Information
Table 120. Serum Institute Description and Overview
Table 121. Serum Institute Vaccine for Non-infectious Meningitis Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 122. Serum Institute Vaccine for Non-infectious Meningitis Product and Services
Table 123. Serum Institute Vaccine for Non-infectious Meningitis SWOT Analysis
Table 124. Serum Institute Recent Developments
Table 125. Sanofi SA Company Information
Table 126. Sanofi SA Description and Overview
Table 127. Sanofi SA Vaccine for Non-infectious Meningitis Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 128. Sanofi SA Vaccine for Non-infectious Meningitis Product and Services
Table 129. Sanofi SA Vaccine for Non-infectious Meningitis SWOT Analysis
Table 130. Sanofi SA Recent Developments
Table 131. Pfizer Company Information
Table 132. Pfizer Description and Overview
Table 133. Pfizer Vaccine for Non-infectious Meningitis Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 134. Pfizer Vaccine for Non-infectious Meningitis Product and Services
Table 135. Pfizer Vaccine for Non-infectious Meningitis SWOT Analysis
Table 136. Pfizer Recent Developments
Table 137. Nuron Biotech Company Information
Table 138. Nuron Biotech Description and Overview
Table 139. Nuron Biotech Vaccine for Non-infectious Meningitis Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 140. Nuron Biotech Vaccine for Non-infectious Meningitis Product and Services
Table 141. Nuron Biotech Vaccine for Non-infectious Meningitis SWOT Analysis
Table 142. Nuron Biotech Recent Developments
Table 143. JN-International Medical Company Information
Table 144. JN-International Medical Description and Overview
Table 145. JN-International Medical Vaccine for Non-infectious Meningitis Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 146. JN-International Medical Vaccine for Non-infectious Meningitis Product and Services
Table 147. JN-International Medical Vaccine for Non-infectious Meningitis SWOT Analysis
Table 148. JN-International Medical Recent Developments
Table 149. Key Raw Materials Lists
Table 150. Raw Materials Key Suppliers Lists
Table 151. Vaccine for Non-infectious Meningitis Distributors List
Table 152. Vaccine for Non-infectious Meningitis Customers List
Table 153. Vaccine for Non-infectious Meningitis Market Trends
Table 154. Vaccine for Non-infectious Meningitis Market Drivers
Table 155. Vaccine for Non-infectious Meningitis Market Challenges
Table 156. Vaccine for Non-infectious Meningitis Market Restraints
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine for Non-infectious Meningitis Product Picture
Figure 2. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Vaccine for Non-infectious Meningitis Market Share by Type in 2022 & 2034
Figure 4. Polysaccharide Vaccines Product Picture
Figure 5. Conjugate Vaccines Product Picture
Figure 6. Combination Vaccines Product Picture
Figure 7. Men B Vaccines Product Picture
Figure 8. Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Vaccine for Non-infectious Meningitis Market Share by Application in 2022 & 2034
Figure 10. Meningitis
Figure 11. Septicemia
Figure 12. Others
Figure 13. Vaccine for Non-infectious Meningitis Report Years Considered
Figure 14. Global Vaccine for Non-infectious Meningitis Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Vaccine for Non-infectious Meningitis Revenue 2018-2034 (US$ Million)
Figure 16. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Vaccine for Non-infectious Meningitis Sales Quantity 2018-2034 (K Units)
Figure 18. Global Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Vaccine for Non-infectious Meningitis Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Vaccine for Non-infectious Meningitis Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Vaccine for Non-infectious Meningitis Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Vaccine for Non-infectious Meningitis Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Vaccine for Non-infectious Meningitis Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Vaccine for Non-infectious Meningitis Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Vaccine for Non-infectious Meningitis Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Vaccine for Non-infectious Meningitis Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Vaccine for Non-infectious Meningitis Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Vaccine for Non-infectious Meningitis Revenue in 2022
Figure 32. Vaccine for Non-infectious Meningitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
Figure 35. Global Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
Figure 37. North America Vaccine for Non-infectious Meningitis Revenue Market Share by Company in 2022
Figure 38. North America Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Company in 2022
Figure 39. North America Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
Figure 41. North America Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
Figure 43. North America Vaccine for Non-infectious Meningitis Revenue Share by Country (2018-2034)
Figure 44. North America Vaccine for Non-infectious Meningitis Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Company in 2022
Figure 48. Europe Vaccine for Non-infectious Meningitis Revenue Market Share by Company in 2022
Figure 49. Europe Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
Figure 51. Europe Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
Figure 53. Europe Vaccine for Non-infectious Meningitis Revenue Share by Country (2018-2034)
Figure 54. Europe Vaccine for Non-infectious Meningitis Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 56. France Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 60. China Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Company in 2022
Figure 61. China Vaccine for Non-infectious Meningitis Revenue Market Share by Company in 2022
Figure 62. China Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
Figure 64. China Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
Figure 66. APAC Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Company in 2022
Figure 67. APAC Vaccine for Non-infectious Meningitis Revenue Market Share by Company in 2022
Figure 68. APAC Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
Figure 70. APAC Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
Figure 72. APAC Vaccine for Non-infectious Meningitis Revenue Share by Region (2018-2034)
Figure 73. APAC Vaccine for Non-infectious Meningitis Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 78. India Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue Share by Country (2018-2034)
Figure 87. Brazil Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Vaccine for Non-infectious Meningitis Revenue (2018-2034) & (US$ Million)
Figure 92. Vaccine for Non-infectious Meningitis Value Chain
Figure 93. Vaccine for Non-infectious Meningitis Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed